{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:57:11Z","timestamp":1792065431140,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.adro.2026.102125","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:58:30Z","timestamp":1782230310000},"page":"102125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dosimetric and Clinical Impact of Bone Marrow-sparing Radiation Therapy for Anal Cancer: A Systematic Review"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-6665","authenticated-orcid":false,"given":"Jasmine","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Leech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olive","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouhi","family":"Fazelzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hosni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2026.102125_bib0001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijrobp.2019.10.016","article-title":"Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma","volume":"106","author":"Shakir","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0002","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0003","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.adro.2026.102125_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.adro.2026.102125_bib0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1440-1673.1962.tb01112.x","article-title":"Bone marrow distribution as a factor in estimating radiation to the blood-forming organ: A survey of present knowledge","volume":"6","author":"Atkinson","year":"1962","journal-title":"J Coll Radiol Australas"},{"key":"10.1016\/j.adro.2026.102125_bib0006","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-S","article-title":"Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy","volume":"31","author":"Mauch","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0007","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2009.11.040","article-title":"Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging","volume":"79","author":"Hayman","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0008","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1120\/jacmp.v15i4.4780","article-title":"Spatial mapping of functional pelvic bone marrow using FLT PET","volume":"15","author":"McGuire","year":"2014","journal-title":"J Appl Clin Med Phys."},{"key":"10.1016\/j.adro.2026.102125_bib0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40658-022-00495-7","article-title":"Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90","volume":"9","author":"Hemmingsson","year":"2022","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury-mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr Cancer Ther Rev"},{"key":"10.1016\/j.adro.2026.102125_bib0011","first-page":"142","article-title":"Mitomycin\u2013C-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: Cumulative toxicity of an old drug in a new era","volume":"10","author":"El-Ghazal","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.adro.2026.102125_bib0012","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2016.04.009","article-title":"Using [(18)F]fluorothymidine imaged with positron emission tomography to quantify and reduce hematologic toxicity due to chemoradiation therapy for pelvic cancer patients","volume":"96","author":"McGuire","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0013","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbcan.2017.05.001","article-title":"The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy","volume":"1868","author":"Martin","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.adro.2026.102125_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103497","article-title":"The impact of pelvic nodal radiotherapy on hematologic toxicity: A systematic review with focus on leukopenia, lymphopenia and future perspectives in prostate cancer treatment","volume":"168","author":"Iorio","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.adro.2026.102125_bib0015","series-title":"Critical appraisal tools","year":"2020"},{"key":"10.1016\/j.adro.2026.102125_bib0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12874-017-0391-8","article-title":"Clarifying the distinction between case series and cohort studies in systematic reviews of comparative studies: Potential impact on body of evidence and workload","volume":"17","author":"Mathes","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.adro.2026.102125_bib0017","series-title":"Covidence systematic review software","author":"Innovation","year":"2025"},{"key":"10.1016\/j.adro.2026.102125_bib0018","unstructured":"Statology. Cohen's kappa statistic. Accessed February 22, 2021. https:\/\/www.statology.org\/cohens-kappa-statistic\/"},{"key":"10.1016\/j.adro.2026.102125_bib0019","series-title":"GRADE handbook for grading quality of evidence and strength of recommendations","year":"2013"},{"key":"10.1016\/j.adro.2026.102125_bib0020","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijrobp.2005.02.030","article-title":"Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: Toxicity and clinical outcome","volume":"63","author":"Milano","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1748-717X-2-41","article-title":"Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: A comparison of conventional and IMRT plans","volume":"2","author":"Menkarios","year":"2007","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0022","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","article-title":"Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"70","author":"Mell","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0023","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1748-717X-5-92","article-title":"Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer","volume":"5","author":"Vieillot","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0024","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijrobp.2011.12.072","article-title":"Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal","volume":"84","author":"Bazan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1748-717X-7-45","article-title":"IMRT for locally advanced anal cancer: Clinical experience of the Montpellier Cancer Center","volume":"7","author":"Vieillot","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0026","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijrobp.2012.04.044","article-title":"Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies","volume":"85","author":"Liang","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0027","first-page":"87983","article-title":"Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy","author":"Bazan","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0028","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.prro.2013.07.011","article-title":"Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal","volume":"4","author":"Cheng","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0029","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3109\/0284186X.2014.1002570","article-title":"Pencil-beam scanning proton therapy for anal cancer: A dosimetric comparison with intensity-modulated radiotherapy","volume":"54","author":"Ojerholm","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13014-015-0398-4","article-title":"Intensity-modulated radiotherapy (IMRT) vs helical tomotherapy (HT) in concurrent chemoradiotherapy (CRT) for patients with anal canal carcinoma (ACC): An analysis of dose distribution and toxicities","volume":"10","author":"Yeung","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0031","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.radonc.2015.08.008","article-title":"Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer","volume":"117","author":"Joseph","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0032","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2015.09.009","article-title":"Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer","volume":"117","author":"Robinson","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0033","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.radonc.2015.10.027","article-title":"Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer","volume":"117","author":"Anand","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0034","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/0284186X.2015.1043396","article-title":"Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma","volume":"55","author":"Julie","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0035","first-page":"70","article-title":"Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: A prospective study","volume":"4","author":"Rattan","year":"2016","journal-title":"Ann Transl Med."},{"key":"10.1016\/j.adro.2026.102125_bib0036","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2015.12.006","article-title":"Irradiation of FDG-PET-defined active bone marrow subregions and acute hematologic toxicity in anal cancer patients undergoing chemoradiation","volume":"94","author":"Rose","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0037","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12032-016-0789-x","article-title":"Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients","volume":"33","author":"Franco","year":"2016","journal-title":"Med Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0038","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12032-016-0852-7","article-title":"Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation","volume":"33","author":"Franco","year":"2016","journal-title":"Med Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0039","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijrobp.2016.10.010","article-title":"Hematologic Nadirs during chemoradiation for anal cancer: Temporal characterization and dosimetric predictors","volume":"97","author":"Lee","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12094-016-1504-2","article-title":"Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer","volume":"19","author":"Franco","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0041","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1186\/s12885-017-3708-4","article-title":"Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation","volume":"17","author":"Franco","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2026.102125_bib0042","doi-asserted-by":"crossref","first-page":"11","DOI":"10.14338\/IJPT-17-00017","article-title":"Dosimetric comparison of intensity-modulated proton therapy and volumetric-modulated arc therapy in anal cancer patients and the ability to spare bone marrow","volume":"4","author":"Meier","year":"2017","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.adro.2026.102125_bib0043","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/0284186X.2017.1377847","article-title":"The volume of PET-defined, active bone marrow spared predicts acute hematologic toxicities in anal cancer patients receiving concurrent chemoradiotherapy","volume":"57","author":"Freese","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0044","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13566-017-0329-0","article-title":"Absolute volume of active bone marrow and total bone marrow spared in anal cancer patients using intensity modulated proton versus volumetric arc therapy","volume":"7","author":"Prasad","year":"2018","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0045","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.adro.2019.06.005","article-title":"18F-FDG PET predicts hematologic toxicity in patients with locally advanced anal cancer treated with chemoradiation","volume":"4","author":"David","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0046","doi-asserted-by":"crossref","first-page":"288","DOI":"10.14735\/amko2020288","article-title":"Haematotoxicity in IMRT\/VMAT curatively treated anal cancer. Hematologick\u00e1 toxicita u IMRT\/VMAT v kurativn\u00ed l\u00e9\u010db\u011b an\u00e1ln\u00edho karcinomu","volume":"33","author":"Lohynsk\u00e1","year":"2020","journal-title":"Klin Onkol."},{"key":"10.1016\/j.adro.2026.102125_bib0047","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.radonc.2019.08.016","article-title":"Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer","volume":"143","author":"Robinson","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0048","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/jpm11050427","article-title":"Concurrent chemoradiation in anal cancer patients delivered with bone marrow-sparing IMRT: Final results of a prospective phase II trial","volume":"11","author":"Arcadipane","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.adro.2026.102125_bib0049","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13014-021-01876-5","article-title":"Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer","volume":"16","author":"Nilsson","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0050","article-title":"Multi-institutional comparison of intensity modulated photon versus proton radiation therapy in the management of squamous cell carcinoma of the anus","volume":"6","author":"Mohiuddin","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0051","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/COC.0000000000000916","article-title":"Hematologic toxicity comparison of intensity modulated proton therapy and intensity modulated radiation therapy in anal cancer patients","volume":"45","author":"Nelson","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.11.018","article-title":"Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer","volume":"178","author":"Lukovic","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0053","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.clon.2015.08.006","article-title":"Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions","volume":"27","author":"Yates","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.adro.2026.102125_bib0054","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative analyses of normal tissue effects in the clinic (QUANTEC): An introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0055","doi-asserted-by":"crossref","first-page":"20439","DOI":"10.18632\/oncotarget.24926","article-title":"The ongoing challenge of large anal cancers: Prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy","volume":"9","author":"Hosni","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.adro.2026.102125_bib0056","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12885-021-08187-8","article-title":"Patterns of pathologic lymph nodes in anal cancer: A PET-CT-based analysis with implications for radiotherapy treatment volumes","volume":"21","author":"Frennered","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2026.102125_bib0057","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2014.02.018","article-title":"Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors","volume":"63","author":"Green","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.adro.2026.102125_bib0058","article-title":"Pelvic insufficiency fractures and bone pain after radiation therapy for anal cancer: Relation to pelvic bone dose-volume parameters","volume":"8","author":"Kronborg","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0059","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.radonc.2005.06.017","article-title":"Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies","volume":"77","author":"Roeske","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0060","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1007\/s00259-012-2141-9","article-title":"Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET\/CT imaging","volume":"39","author":"Sambuceti","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.adro.2026.102125_bib0061","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s003300050547","article-title":"Magnetic resonance imaging of normal bone marrow","volume":"8","author":"Vande Berg","year":"1998","journal-title":"Eur Radiol"},{"key":"10.1016\/j.adro.2026.102125_bib0062","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.nucmedbio.2006.09.005","article-title":"Correlations between 18F-FDG uptake by bone marrow and hematological parameters: Measurements by PET\/CT","volume":"33","author":"Murata","year":"2006","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.adro.2026.102125_bib0063","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.radonc.2021.10.015","article-title":"Pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis","volume":"165","author":"Zhou","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1201500","article-title":"A review on lymphocyte radiosensitivity and its impact on radiotherapy","volume":"13","author":"Paganetti","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0065","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.ijrobp.2023.01.054","article-title":"Predicting severity of radiation induced lymphopenia in individual proton therapy patients for varying dose rate and fractionation using dynamic 4-dimensional blood flow simulations","volume":"116","author":"McCullum","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102125_bib0066","article-title":"Association of circulating inflammatory biomarker levels and toxicity in patients undergoing pelvic radiation for cancer: A critical review","volume":"10","author":"Fess\u00e9","year":"2025","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102125_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110041","article-title":"Modeling frameworks for radiation induced lymphopenia: A critical review","volume":"190","author":"Cella","year":"2024","journal-title":"Radiother Oncol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426001326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426001326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:36:01Z","timestamp":1792064161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109426001326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2452109426001326"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2026.102125","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric and Clinical Impact of Bone Marrow-sparing Radiation Therapy for Anal Cancer: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2026.102125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102125"}}